Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.

HDAX Therapeutics is developing next-generation HDAC6 inhibitors to treat neurological and cardiometabolic diseases.